Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy

Jayastu Senapati, Hagop Kantarjian, Farhad Ravandi, Courtney D. DiNardo, Koichi Takahashi, Danielle Hammond, Koji Sasaki, Kelly S. Chien, Rashmi Kanagal-Shamanna, Uday R Popat, Sherry A. Pierce, Elias Jabbour, Richard E Champlin, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 8652–8654.

https://doi.org/10.1182/blood-2022-170447

Published: 2022

Journal Articles

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

Sai Prasad Desikan, Hagop Kantarjian, Elias Jabbour, Kelly S. Chien, Guillermo Montalban-Bravo, Yesid Alvarado, Gautam Borthakur, Ghayas C. Issa, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Danielle Hammond, Abhishek Maiti, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3301–3303.

https://doi.org/10.1182/blood-2022-169824

Published: 2022

Journal Articles

Short Telomere Syndromes and Inherited Predisposition to Bone Marrow Diseases: The MDACC Experience

Alex Bataller, Yoheved Gerstein, Naveen Pemmaraju, Danielle Hammond, Hussein A. Abbas, Ghayas C. Issa, Koichi Takahashi, Tapan M. Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 11463–11465.

https://doi.org/10.1182/blood-2022-164954

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Blood (2022) 140 (Supplement 1): 6064–6066.

https://doi.org/10.1182/blood-2022-170458

Published: 2022

Journal Articles

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, Nicholas Short, Abhishek Maiti, Hussein A Abbas, Naval Daver, Naveen Pemmaraju, Sherry A. Pierce, Kelly S. Chien, Koji Sasaki, Danielle Hammond, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 1427–1429.

https://doi.org/10.1182/blood-2022-169934

Published: 2022

Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4036–4038.

https://doi.org/10.1182/blood-2022-170069

Published: 2022

Journal Articles

A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Gautham Borthakur, Kelly S. Chien, Danielle Hammond, Rajani K Medury, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9816–9817.

https://doi.org/10.1182/blood-2022-170185

Published: 2022

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 6952–6954.

https://doi.org/10.1182/blood-2022-165488

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Alex Bataller, Rashmi Kanagal-Shamanna, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Nicholas Short, Gautam Borthakur, Elias Jabbour, Danielle Hammond, Lucia Masarova, Irene Ganan-Gomez, Vera Adema, Hagop Kantarjian, Guillermo Garcia-Manero, Koji Sasaki

Blood (2022) 140 (Supplement 1): 9793–9795.

https://doi.org/10.1182/blood-2022-164962

Published: 2022

Journal Articles

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Sangeetha Venugopal, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Koji Sasaki, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Nicholas J. Short, Ghayas C. Issa, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2021-153475

Published: 2021

Journal Articles

Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia

Danielle Hammond, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Nicholas J. Short, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Elias J. Jabbour, Kelly S. Chien, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2021) 138 (Supplement 1): 1224.

https://doi.org/10.1182/blood-2021-153941

Published: 2021

Journal Articles

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142469

Published: 2020

Journal Articles

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136385

Published: 2020

Journal Articles

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-139901

Published: 2020

Journal Articles

Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Danielle Hammond, MD, Sanam Loghavi, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Maro Ohanian, DO, Ghayas C. Issa, MD, Yesid Alvarado, MD, Guillermo Montalban-Bravo, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Koichi Takahashi, MD PhD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141380

Published: 2020

Journal Articles

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Blood (2020) 136 (Supplement 1): 26–29.

https://doi.org/10.1182/blood-2020-137212

Published: 2020

NARROW

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

Short Telomere Syndromes and Inherited Predisposition to Bone Marrow Diseases: The MDACC Experience

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only